Consensus on the Use of Oral Isotretinoin in Dermatology - Brazilian Society of Dermatology

    October 2020 in “ Anais Brasileiros de Dermatologia
    Ediléia Bagatin, Caroline Sousa Costa, Marco Rocha, Fabíola Rosa Picosse, Cristhine Kamamoto, Rodrigo Pirmez, Mayra Ianhez, Hélio Amante Miot
    Image
    Studysummary This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use. Our plain-language summary of this paper — not a Tressless recommendation.
    The document from the Brazilian Society of Dermatology provides a consensus on the use of oral isotretinoin in dermatology, highlighting its efficacy in treating acne, including scar correction, and its potential use in other conditions such as refractory rosacea, severe seborrheic dermatitis, advanced photoaging, and frontal fibrosing alopecia. The consensus, formed by eight experts using the DELPHI methodology, recommends conventional or low doses of isotretinoin for better adherence and tolerability, with a total approved dose for acne treatment being 120 to 150 mg/kg. It also addresses the management of side effects, laboratory monitoring, and the safety of dermatological procedures during treatment, concluding that isotretinoin does not increase the risk of psychiatric disorders or inflammatory bowel disease. The document emphasizes the need for further research to establish optimal dosing and treatment duration for various dermatological conditions treated with isotretinoin and the careful consideration of its teratogenic risks, especially in women of childbearing age.
    Discuss this study in the Community →

    Research cited in this study

    15 / 15 results